Anti-CD20 ADC Therapy for BTK-Refractory Mantle Cell Lymphoma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for relapsed or refractory mantle cell lymphoma (R/R MCL) after BTK inhibitor therapy are inadequate, leading to high recurrence rates and poor survival outcomes, with no effective second-line or beyond regimens available.
Innovation Solution
The use of an anti-CD20 antibody drug conjugate (ADC) with a drug antibody ratio (DAR) of 4.2 ± 1, specifically TRS005, in combination with pharmaceutically acceptable carriers, for administering to patients who have received at least two standard treatments, including BTK inhibitors, to treat R/R MCL.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If BTK inhibitors (Ibrutinib, Zanubrutinib) are used for treating relapsed MCL, then prognosis is improved and safety is maintained, but median progression-free survival only improves to about 2 years and disease eventually progresses in almost all patients
Solution Approach 1:
The patent changes the therapeutic parameter from BTK inhibition to CD20-targeted antibody-drug conjugate therapy with specific DAR values (4.2±0.5), transforming the mechanism of action to achieve sustained response in R/R MCL patients who progressed on BTK inhibitors
Solution Approach 2:
The patent uses a composite therapeutic approach combining monoclonal antibody (Rituximab or biosimilar) with cytotoxic drugs (MMAE or DM1) at specific ratios (DAR 4.2±0.5), creating an antibody-drug conjugate that delivers targeted cytotoxicity to CD20-expressing MCL cells
2Object-affected harmful factors
If BTK inhibitor treatment is administered to MCL patients, then good safety profile is achieved, but median overall survival remains less than 1 year for patients who develop progression
Solution Approach 1:
The patent transitions from small-molecule BTK inhibitor therapy to antibody-drug conjugate therapy with optimized drug-antibody ratios, changing the therapeutic parameter to achieve both safety and improved overall survival in R/R MCL patients
3Adaptability or versatility
If standard treatment regimens are used for R/R MCL after at least two prior treatments, then treatment options are limited, but no effective treatment regimen is available especially after BTK inhibitor treatment
Solution Approach 1:
The patent introduces a new therapeutic parameter (anti-CD20 ADC with DAR 4.2±0.5) that is effective in R/R MCL patients who have received at least two prior treatments including BTK inhibitors, expanding treatment options with proven efficacy
Solution Approach 2:
The patent uses anti-CD20 antibody as an intermediary that targets CD20-expressing MCL cells and delivers cytotoxic payload selectively to tumor cells, providing effective treatment for R/R MCL patients with limited options
Data Source
AI summary
The present disclosure discloses a use of anti-CD20 antibody drug conjugate (ADC) in the preparation of a drug for treating Mantle Cell Lymphoma (MCL). The drug has good clinical efficacy in treating relapsed or refractory mantle cell lymphoma (R/R MCL), is safe and controllable, and meets the currently unmet clinical needs.